Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMLYZOG)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Norbinaltorphimine; nor-Binaltorphimine; UNII-36OOQ86QM1; 36OOQ86QM1; CHEBI:81529; C18130; 4,8:11,15-Dimethano-20H-bisbenzofuro(2,3-a:3',2'-i)dipyrido(4,3-b:3',4'-h)carbazole-1,8a,10a,18-tetrol, 7,12-bis(cyclopropylmethyl)-5,6,7,8,9,10,11,12,13,14,19a,20b-dodecahydro-20-methyl-, (8R-(4bR*,8alpha,8abeta,10aalpha,11beta,14aR*,19aalpha,20bbeta))-; Nor-Binaltorphamine; (-)-norbinaltorphimine; NOR-BNI (HCI)2; Lopac0_000806; GTPL1642; CHEMBL573214; SCHEMBL12013206; BDBM82551; APSUXPSYBJVPPS-YAUKWVCOSA-N
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
